The promise of third-generation recombinant therapy and gene therapy

Seminars in Hematology

Volumn 40, Issue 3 SUPPL. 3, 2003, Pages 23-28

  Manno, Catherine S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B DOMAIN DELETED RECOMBINANT BLOOD CLOTTING FACTOR 8; COAGULIN B; COMPLEMENTARY DNA; HELIXATE FS; HUMAN ALBUMIN; MAX AD; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; BLOOD COMPONENT THERAPY; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MANUFACTURE; DRUG PURITY; DRUG QUALITY; DRUG SAFETY; DRUG SCREENING; GENE INSERTION; GENE THERAPY; HEMOPHILIA; HEMOPHILIA A; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNOTOXICITY; LICENSING; LONG TERM EXPOSURE; MUTAGENESIS; NONVIRAL GENE DELIVERY SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTHROMBIN TIME; REVIEW; THROMBOCYTOPENIA; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 79952678426     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(03)80756-4     Document Type: Article

References (12)

1. National Hemophilia Foundation: MASAC Recommendations #135: MASAC recommendation concerning the treatment of hemophilia and other bleeding disorders (revised November 2002). Washington, DC, National Hemophilia Foundation. Available at: http://www.hemophilia.org/programs/masac/masac/masac135.htm. Accessed February 12, 2003
2. Tabor E: The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39:1160-1168, 1999
3. Powell JS, Ragni MV, White GC, et al: Phase I trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Thromb Haemost 86:OC2489, 2001 (suppl, abstr)
4. Roth DA, Tawa NE Jr, O'Brien JM, et al: Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 344:1735-1742, 2001
5. Manno CS, Glader B, Ragni MV, et al: A phase I trial of AAV-mediated muscle directed gene transfer for hemophilia B. Blood 96:801a, 2000 (suppl 1, abstr)
6. Manno CS, Chew AJ, Hutchinson S, et al: AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963-2972, 2003
7. Reddy PS, Sakhuja K, Ganesh S, et al: Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 5:63-73, 2002
8. GenStar: GenStar reports clinical results of the first patient to receive MAX-AD™ FVIII treatment for hemophilia A [press release]. July 11, 2001. Available at: http://www.genstarrx.com/news/mainnews_frame.html. Accessed February 11, 2003
9. Miao CH, Nakai H, Thompson AR, et al: Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: Cell cycling does not influence hepatocyte transduction. J Virol 74:3793-3803, 2000
10. Nakai H, Thomas CE, Storm TA, et al: A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol 76:11343-11349, 2002
11. Qing K, Kliuntirat B, Mah C, et al: Adeno-associated virus type 2-mediated gene transfer: Correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J Virol 72:1593-1599, 1998
12. Kay MA, High KA, Glader B, et al: A phase I/II clinical trial for liver directed AAV-mediated gene transfer for severe hemophilia B. Blood 100:115a, 2002 (suppl 1, abstr)